ADCT (ADC Therapeutics SA)
Insider Trading Activity
Every open-market purchase and sale reported by ADCT officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-02 | Jose Carmona | Chief Financial Officer | A | — | — |
| 2026-07-02 | Mohamed Zaki | Chief Medical Officer | A | — | — |
| 2026-07-02 | PETER J GRAHAM | Chief Legal Officer | A | — | — |
| 2026-07-02 | AMEET MALLIK | Chief Executive Officer | A | — | — |
| 2026-06-03 | Timothy Coughlin | Director | MIXED | — | — |
| 2026-06-03 | Robert Azelby | Director | MIXED | — | — |
| 2026-06-03 | JEAN-PIERRE BIZZARI | Director | MIXED | — | — |
| 2026-06-03 | Ron Squarer | Director | MIXED | — | — |
| 2026-06-03 | Victor Sandor | Director | MIXED | — | — |
| 2026-06-03 | Peter Hug | Director | MIXED | — | — |
| 2026-06-03 | Viviane Monges | Director | MIXED | — | — |
| 2026-04-02 | Redmile Group, LLC | 10%+ Owner | Sell | — | — |
| 2026-02-18 | Lisa Michelle Kallebo | Chief Accounting Officer | MIXED | — | — |
| 2026-02-18 | PETER J GRAHAM | Chief Legal Officer | MIXED | — | — |
| 2026-02-18 | Jose Carmona | Chief Financial Officer | MIXED | — | — |
| 2026-02-18 | AMEET MALLIK | Chief Executive Officer | MIXED | — | — |
| 2026-02-18 | Mohamed Zaki | Chief Medical Officer | MIXED | — | — |
| 2025-12-09 | Lisa Michelle Kallebo | Chief Accounting Officer | F | — | — |
| 2025-12-09 | PETER J GRAHAM | Chief Legal Officer | F | — | — |
| 2025-12-09 | Mohamed Zaki | Chief Medical Officer | F | — | — |
| 2025-12-09 | Jose Carmona | Chief Financial Officer | F | — | — |
| 2025-12-09 | AMEET MALLIK | Chief Executive Officer | F | — | — |
| 2025-10-28 | RedCo II Master Fund, L.P. | 10%+ Owner | Buy | — | — |
| 2025-06-17 | Viviane Monges | Director | F | — | — |
| 2025-06-17 | Victor Sandor | Director | F | — | — |
| 2025-06-17 | Ron Squarer | Director | F | — | — |
| 2025-06-17 | JEAN-PIERRE BIZZARI | Director | F | — | — |
| 2025-06-17 | Robert Azelby | Director | F | — | — |
| 2025-06-17 | Peter Hug | Director | F | — | — |
| 2025-06-13 | RedCo II Master Fund, L.P. | 10%+ Owner | Buy | — | — |
| 2025-06-05 | Peter Hug | Director | A | — | — |
| 2025-06-05 | Victor Sandor | Director | A | — | — |
| 2025-06-05 | Viviane Monges | Director | A | — | — |
| 2025-06-05 | Ron Squarer | Director | A | — | — |
| 2025-06-05 | TIMOTHY COUGHLIN | Director | A | — | — |
| 2025-06-05 | JEAN-PIERRE BIZZARI | Director | A | — | — |
| 2025-06-05 | Robert Azelby | Director | A | — | — |
| 2025-05-19 | HANS PETER WILD | 10%+ Owner | J | — | — |
| 2025-05-19 | Thomas Pfisterer | — | J | — | — |
| 2025-05-08 | AMEET MALLIK | Chief Executive Officer | F | — | — |
| 2025-02-14 | Jose Carmona | Chief Financial Officer | A | — | — |
| 2025-02-14 | AMEET MALLIK | Chief Executive Officer | A | — | — |
| 2025-02-14 | Mohamed Zaki | Chief Medical Officer | A | — | — |
| 2025-02-14 | Lisa Michelle Kallebo | Chief Accounting Officer | A | — | — |
| 2025-02-14 | PETER J GRAHAM | Chief Legal Officer | A | — | — |
| 2024-12-13 | Jeremy Green | 10%+ Owner | Buy | — | — |
| 2024-12-09 | PETER J GRAHAM | Chief Legal Officer | F | — | — |
| 2024-12-09 | Lisa Michelle Kallebo | Chief Accounting Officer | F | — | — |
| 2024-12-09 | Mohamed Zaki | Chief Medical Officer | F | — | — |
| 2024-12-09 | Jose Carmona | Chief Financial Officer | F | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 28,762,443 | — |
| — | 10%+ Owner | 25,735,799 | — |
| — | 10%+ Owner | 9,788,944 | — |
| — | Chief Executive Officer | 2,790,870 | — |
| — | Chief Financial Officer | 938,076 | — |
| — | Chief Medical Officer | 896,317 | — |
| — | Chief Legal Officer | 841,640 | — |
| — | Director | 625,755 | — |
| — | Director | 263,344 | — |
| — | Director | 186,447 | — |
| — | Director | 151,902 | — |
| — | Director | 140,686 | — |
| — | Director | 138,627 | — |
| — | Chief Accounting Officer | 128,224 | — |
| — | Director | 112,805 | — |
| — | Director | 72,400 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ADCT quote page; the site-wide leaderboard is on the insider transactions hub.